Skip to main content
Vaxcell-Bio Therapeutics logo

Vaxcell-Bio Therapeutics — Investor Relations & Filings

Ticker · 323990 ISIN · KR7323990002 KO Manufacturing
Open in API
Filings indexed 228 across all filing types
Latest filing 2026-03-27 Director's Dealing
Country KR South Korea
Listing KO 323990

About Vaxcell-Bio Therapeutics

https://vaxcell-bio.com/en/

Vaxcell-Bio Therapeutics is a biotechnology company specializing in the research and development of innovative immunotherapies. The company's primary focus is on oncology, developing a pipeline of cell-based and protein-based treatments, including immune cell therapies and targeted protein-degrading therapeutics. In addition to its core focus on cancer, Vaxcell-Bio is expanding its research into other areas, such as developing drug delivery system (DDS)-based therapies for conditions like macular degeneration.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a regulatory filing entitled “임원ㆍ주요주주 특정증권등 소유상황보고서” (Report on the Ownership Status of Specific Securities by Directors and Major Shareholders) submitted to the Securities and Futures Commission and Korea Exchange. It details shareholdings of an executive (director) and changes in those holdings, including transaction dates, share counts, and ownership ratios. This matches the definition of a Director’s Dealing report (insider transactions by directors/executives).
2026-03-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a mandatory disclosure filed with the Financial Services Commission and Korea Exchange by an executive (“임원ㆍ주요주주 특정증권등 소유상황보고서”). It details the director’s name, share counts at two dates, changes in ownership, acquisition method (market purchase), volume and price. This matches the definition of a Director's Dealing report (insider share transactions by company directors/executives).
2026-03-27 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is the detailed results of the Annual General Meeting held on 2026-03-24, listing approval of financial statements, voting on director and auditor remuneration limits, and vote tallies with percentages. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-03-24 Korean
사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the 16th fiscal year (2025) of VaxCell-Bio. It contains comprehensive sections including company overview, business details, financial statements, management discussion and analysis, and governance information. This structure corresponds to the standard annual filing required by the Financial Supervisory Service in South Korea, which is equivalent to a 10-K filing. FY 2025
2026-03-16 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides the auditor's opinion, key financial data, and confirmation of the audit completion for the fiscal year. While it contains financial data, it is a summary announcement of the audit report submission rather than the full annual report (10-K) or a standalone audit report (AR). According to the 'Menu vs Meal' rule, this is a notification of the filing of the audit report, which falls under the category of Report Publication Announcement (RPA). FY 2025
2026-03-16 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) for Vaxcell-Bio. It contains detailed information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, voting procedures, and proxy solicitation details. While it contains financial statements (balance sheet, income statement, etc.) as part of the meeting agenda, the primary regulatory purpose of this specific filing is to solicit proxies from shareholders for the AGM. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2026-03-04 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.